Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study

Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study

Abstract Objectives Acquired resistance represents a bottleneck to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung cancer. Our study aimed to explore the efficacy of antiangiogenic‐based therapy in osimertinib‐resistant NSCLC patients and assess the efficacy...

Full description

Bibliographic Details
Main Authors: Ya Chen, Hongyu Liu, Nana Hu, Yanan Wang, Zhengyu Yang, Junqiang Zhang, Baohui Han
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Cancer Medicine
Subjects:
anlotinib
non‐small‐cell lung cancer
osimertinib
resistance
Online Access:https://doi.org/10.1002/cam4.6232

Internet

https://doi.org/10.1002/cam4.6232

Similar Items